206 related articles for article (PubMed ID: 29961603)
1. The economic burden of human papillomavirus infection-associated diseases in the Republic of Korea, 2002-2015.
Ki M; Choi HY; Han M; Oh JK
Vaccine; 2018 Jul; 36(31):4633-4640. PubMed ID: 29961603
[TBL] [Abstract][Full Text] [Related]
2. Cost analysis of Human Papillomavirus-related cervical diseases and genital warts in Swaziland.
Ginindza TG; Sartorius B; Dlamini X; Östensson E
PLoS One; 2017; 12(5):e0177762. PubMed ID: 28531205
[TBL] [Abstract][Full Text] [Related]
3. Annual prevalence and economic burden of genital warts in Korea: Health Insurance Review and Assessment (HIRA) service data from 2007 to 2015.
Park YJ; Kim JM; Lee BR; Kim TH; Lee EG
Epidemiol Infect; 2018 Jan; 146(2):177-186. PubMed ID: 29235433
[TBL] [Abstract][Full Text] [Related]
4. Prevalence of human papillomavirus-related diseases in the Republic of Korea: a cross-sectional study.
Oh JK; Choi HY; Han M; Lee JK; Min KJ; Ki M
Sex Transm Infect; 2019 Jun; 95(4):292-299. PubMed ID: 30679392
[TBL] [Abstract][Full Text] [Related]
5. Assessing the annual economic burden of preventing and treating anogenital human papillomavirus-related disease in the US: analytic framework and review of the literature.
Insinga RP; Dasbach EJ; Elbasha EH
Pharmacoeconomics; 2005; 23(11):1107-22. PubMed ID: 16277547
[TBL] [Abstract][Full Text] [Related]
6. The economic burden of human papillomavirus-related precancers and cancers in Sweden.
Östensson E; Silfverschiöld M; Greiff L; Asciutto C; Wennerberg J; Lydrup ML; Håkansson U; Sparén P; Borgfeldt C
PLoS One; 2017; 12(6):e0179520. PubMed ID: 28651012
[TBL] [Abstract][Full Text] [Related]
7. Cost of Preventing, Managing, and Treating Human Papillomavirus (HPV)-Related Diseases in Sweden before the Introduction of Quadrivalent HPV Vaccination.
Östensson E; Fröberg M; Leval A; Hellström AC; Bäcklund M; Zethraeus N; Andersson S
PLoS One; 2015; 10(9):e0139062. PubMed ID: 26398189
[TBL] [Abstract][Full Text] [Related]
8. The Direct Medical Costs of Diseases Associated with Human Papillomavirus Infection in Manitoba, Canada.
Righolt CH; Pabla G; Mahmud SM
Appl Health Econ Health Policy; 2018 Apr; 16(2):195-205. PubMed ID: 29299769
[TBL] [Abstract][Full Text] [Related]
9. Economic burden of human papillomavirus-related diseases in Italy.
Baio G; Capone A; Marcellusi A; Mennini FS; Favato G
PLoS One; 2012; 7(11):e49699. PubMed ID: 23185412
[TBL] [Abstract][Full Text] [Related]
10. The healthcare costs of treating human papillomavirus-related cancers in Norway.
Hylin H; Thrane H; Pedersen K; Kristiansen IS; Burger EA
BMC Cancer; 2019 May; 19(1):426. PubMed ID: 31064346
[TBL] [Abstract][Full Text] [Related]
11. Economic burden of HPV9-related diseases: a real-world cost analysis from Italy.
Mennini FS; Fabiano G; Favato G; Sciattella P; Bonanni P; Pinto C; Marcellusi A
Eur J Health Econ; 2019 Aug; 20(6):829-840. PubMed ID: 30900047
[TBL] [Abstract][Full Text] [Related]
12. Burden of disease associated with cervical cancer in malaysia and potential costs and consequences of HPV vaccination.
Aljunid S; Zafar A; Saperi S; Amrizal M
Asian Pac J Cancer Prev; 2010; 11(6):1551-9. PubMed ID: 21338196
[TBL] [Abstract][Full Text] [Related]
13. Cost-effectiveness analysis of the introduction of the human papillomavirus vaccine in Honduras.
Aguilar IB; Mendoza LO; García O; Díaz I; Figueroa J; Duarte RM; Perdomo G; Garcia AG; Janusz CB
Vaccine; 2015 May; 33 Suppl 1():A167-73. PubMed ID: 25919157
[TBL] [Abstract][Full Text] [Related]
14. Epidemiological and economic burden of potentially HPV-related cancers in France.
Abramowitz L; Lacau Saint Guily J; Moyal-Barracco M; Bergeron C; Borne H; Dahlab A; Bresse X; Uhart M; Cancalon C; Catella L; Bénard S
PLoS One; 2018; 13(9):e0202564. PubMed ID: 30235216
[TBL] [Abstract][Full Text] [Related]
15. Economic burden of seasonal influenza in the United States.
Putri WCWS; Muscatello DJ; Stockwell MS; Newall AT
Vaccine; 2018 Jun; 36(27):3960-3966. PubMed ID: 29801998
[TBL] [Abstract][Full Text] [Related]
16. Burden of Disease of Human Papillomavirus (HPV): Hospitalizations in the Marche and Veneto Regions. An observational study.
Mennini FS; Fabiano G; Marcellusi A; Sciattella P; Saia M; Cocchio S; Baldo V
Clin Drug Investig; 2018 Feb; 38(2):173-180. PubMed ID: 29081028
[TBL] [Abstract][Full Text] [Related]
17. Annual cost of hospitalization, inpatient rehabilitation and sick leave of anal cancer in Germany.
Heitland W; Schädlich PK; Chen X; Rémy V; Moro L
J Med Econ; 2013; 16(3):364-71. PubMed ID: 23253056
[TBL] [Abstract][Full Text] [Related]
18. Economic burden of HPV-related cancers in France.
Borget I; Abramowitz L; Mathevet P
Vaccine; 2011 Jul; 29(32):5245-9. PubMed ID: 21616117
[TBL] [Abstract][Full Text] [Related]
19. The Economic Burden of Cancers Attributable to Infection in the Republic of Korea: A Prevalence-Based Study.
Nguyen TXT; Han M; Ki M; Kim YA; Oh JK
Int J Environ Res Public Health; 2020 Oct; 17(20):. PubMed ID: 33086534
[TBL] [Abstract][Full Text] [Related]
20. Cost-effectiveness of HPV vaccination in Belize.
Walwyn L; Janusz CB; Clark AD; Prieto E; Waight E; Largaespada N
Vaccine; 2015 May; 33 Suppl 1():A174-81. PubMed ID: 25919158
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
